用于乳腺癌局部辅助放疗豁免的基因组特征谱的建立与验证
本研究基于两项随机试验(SweBCG91-RT与Princess Margaret)的转录组数据,训练并验证了一个16基因特征谱POLAR,用于预测保乳术后未放疗患者的局部区域复发风险。POLAR低风险患者未放疗时10年局部区域复发率分别为6%和7%,放疗无显著获益;高风险患者放疗显著降低复发风险。
要点
- POLAR低风险患者未放疗时10年局部区域复发率在SweBCG91-RT为6%(95%CI 2-16),Princess Margaret为7%(0-27)。
- POLAR低风险患者放疗无显著获益:SweBCG91-RT的HR为1.1(0.39-3.4,P=.81),Princess Margaret的HR为1.5(0.14-16,P=.74)。
- POLAR高风险患者放疗显著降低局部区域复发风险:SweBCG91-RT的HR为0.43(0.24-0.78,P=.0055),Princess Margaret的HR为0.25(0.07-0.92,P=.038)。
核心结论
- 基于局部区域复发生物学的新型POLAR基因组特征谱可能识别出未接受放疗仍有低局部区域复发风险的患者,从而可能成为豁免放疗的候选人群。
研究设计与样本
- 分析两项随机试验:SweBCG91-RT(I-II期、无辅助全身治疗)和Princess Margaret(年龄50岁及以上、T1-T2、辅助他莫昔芬),均为淋巴结阴性浸润性乳腺癌保乳术后±放疗。
- 采用Affymetrix Human Exon 1.0 ST微阵列进行转录组-wide profiling,纳入雌激素受体阳性/人表皮生长因子受体2阴性且有基因表达数据的患者。
- SweBCG91-RT队列分为训练集(N=243)和验证集(N=354);采用弹性网回归训练16基因特征谱POLAR以预测局部区域复发。
- POLAR在SweBCG91-RT验证集和Princess Margaret队列(N=132)中进行验证。
主要发现
- POLAR低风险且未放疗患者10年局部区域复发率:SweBCG91-RT为6%(95%CI 2-16),Princess Margaret为7%(0-27)。
- POLAR低风险患者放疗无显著获益:SweBCG91-RT的HR为1.1(95%CI 0.39-3.4,P=.81),Princess Margaret的HR为1.5(95%CI 0.14-16,P=.74)。
- POLAR高风险患者放疗显著降低局部区域复发风险:SweBCG91-RT的HR为0.43(95%CI 0.24-0.78,P=.0055),Princess Margaret的HR为0.25(95%CI 0.07-0.92,P=.038)。
- 在合并验证队列中探索性分析放疗与POLAR的交互作用,P=.066。
关键数值与推荐
- POLAR低风险且未放疗10年局部区域复发率:SweBCG91-RT为6%(95%CI 2-16),Princess Margaret为7%(0-27)。
- POLAR低风险患者放疗对比未放疗的局部区域复发风险:SweBCG91-RT的HR为1.1(95%CI 0.39-3.4,P=.81),Princess Margaret的HR为1.5(95%CI 0.14-16,P=.74),均无显著获益。
- POLAR高风险患者放疗对比未放疗的局部区域复发风险:SweBCG91-RT的HR为0.43(95%CI 0.24-0.78,P=.0055),Princess Margaret的HR为0.25(95%CI 0.07-0.92,P=.038),放疗显著降低风险。
- 合并验证队列中放疗与POLAR交互作用检验P=.066。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Adjuvant radiotherapy (RT) is used for women with early-stage invasive breast cancer treated with breast-conserving surgery. However, some women with low risk of recurrence may safely be spared RT. This study aimed to identify these women using a molecular-based approach. METHODS: We analyzed two randomized trials of women with node-negative invasive breast cancer to ± RT following breast-conserving surgery: SweBCG91-RT (stage I-II, no adjuvant systemic therapy) and Princess Margaret (age 50 years or older, T1-T2, adjuvant tamoxifen). Transcriptome-wide profiling was performed (Affymetrix Human Exon 1.0 ST microarray). Patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative tumors and with gene expression data were included. The SweBCG91-RT cohort was divided into training (N = 243) and validation (N = 354) cohorts. A 16-gene signature named Profile for the Omission of Local Adjuvant Radiation (POLAR) was trained to predict locoregional recurrence (LRR) using elastic net regression. POLAR was then validated in the SweBCG91-RT validation cohort and the Princess Margaret cohort (N = 132). RESULTS: Patients categorized as POLAR low-risk without RT had a 10-year LRR of 6% (95% CI, 2 to 16) and 7% (0 to 27) in SweBCG91-RT and Princess Margaret cohorts, respectively. There was no significant benefit from RT in POLAR low-risk patients (hazard ratio [HR], 1.1 [0.39 to 3.4], P = .81, and HR, 1.5 [0.14 to 16], P = .74, respectively). Patients categorized as POLAR high-risk had a significant decreased risk of LRR with RT (HR, 0.43 [0.24 to 0.78], P = .0055, and HR, 0.25 [0.07 to 0.92], P = .038, respectively). An exploratory analysis testing for interaction between RT and POLAR in the combined validation cohort was performed (P = .066). CONCLUSION: The novel POLAR genomic signature on the basis of LRR biology may identify patients with a low risk of LRR despite not receiving RT, and thus may be candidates for RT omission.
引用
- Sjöström M, Fyles A, Liu FF, et al. Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer. J Clin Oncol. 2023. PMID: 36599119. doi:10.1200/JCO.22.00655
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。